Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC

Medical Oncology

Volumn 31, Issue 6, 2014, Pages

  Zhai, Xiaolu ^a   Zhu, Huijun ^a   Wang, Wei ^a   Zhang, Shu ^a   Zhang, Yixin ^a   Mao, Guoxin ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

E cadherin; Hepatocellular carcinoma; Immunohistochemistry; Prognosis; S100A4; Tissue microarray; Vimentin

Indexed keywords

ALPHA FETOPROTEIN; CALVASCULIN; UVOMORULIN; VIMENTIN; CADHERIN; MUC1 PROTEIN, HUMAN; MUCIN 1; PROTEIN S 100; S100A4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR INVASION; AGED; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CADHERINS; CARCINOMA, HEPATOCELLULAR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUCIN-1; PROGNOSIS; S100 PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84905485934     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0970-z     Document Type: Article

References (49)

1. Jemal A, et al. Global cancer statistics. CA Cancer J Clin.2011;61(2):69-90.
2. Parkin DM, et al. Global cancer statistics, 2002. CA Cancer JClin. 2005;55(2):74-108. (Pubitemid 40372904)
3. McGlynn KA, London WT. Epidemiology and natural history ofhepatocellular carcinoma. Best Pract Res Clin Gastroenterol.2005;19(1):3-23. (Pubitemid 40331495)
4. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis:from genes to environment. Nat Rev Cancer. 2006;6(9):674-87. (Pubitemid 44286000)
5. Faivre S, Bouattour M, Raymond E. Novel molecular therapies inhepatocellular carcinoma. Liver Int. 2011;31(Suppl 1):151-60.
6. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of humanhepatocellular carcinoma. Nat Genet. 2002;31(4):339-46.
7. Soini Y, et al. Transcription factors zeb1, twist and snai1 in breastcarcinoma. BMC Cancer. 2011;11:73.
8. Li LP, et al. Subcellular proteomics revealed the epithelial- mesenchymaltransition phenotype in lung cancer. Proteomics. 2011;11(3):429-39.
9. Soltermann A, et al. Prognostic significance of epithelial-mesenchymaland mesenchymal-epithelial transition protein expressionin non-small cell lung cancer. Clin Cancer Res. 2008;14(22):7430-7.
10. van Zijl F, et al. A human model of epithelial to mesenchymaltransition to monitor drug efficacy in hepatocellular carcinomaprogression. Mol Cancer Ther. 2011;10(5):850-60.
11. Yi ZY, et al. Vascular endothelial growth factor receptor-1activation mediates epithelial to mesenchymal transition inhepatocellular carcinoma cells. J Invest Surg. 2011;24(2):67-76.
12. Kim J, et al. Epithelial-mesenchymal transition gene signature topredict clinical outcome of hepatocellular carcinoma. Cancer Sci.2010;101(6):1521-8.
13. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymaltransition. J Clin Invest. 2009;119(6):1420-8.
14. Behrens J, et al. Dissecting tumor cell invasion: epithelial cellsacquire invasive properties after the loss of uvomorulin-mediatedcell-cell adhesion. J Cell Biol. 1989;108(6):2435-47. (Pubitemid 19168932)
15. Okamoto S, et al. Mesenchymal to epithelial transition in thehuman ovarian surface epithelium focusing on inclusion cysts.Oncol Rep. 2009;21(5):1209-14.
16. Thiery JP, et al. Epithelial-mesenchymal transitions in developmentand disease. Cell. 2009;139(5):871-90.
17. Myong NH. Loss of E-cadherin and acquisition of vimentin inepithelial-mesenchymal transition are noble indicators of uterinecervix cancer progression. Korean J Pathol. 2012;46(4):341-8.
18. Kaimori A, et al. Transforming growth factor-beta1 induces anepithelial-to-mesenchymal transition state in mouse hepatocytesin vitro. J Biol Chem. 2007;282(30):22089-101. (Pubitemid 47195788)
19. Guan F, Handa K, Hakomori SI. Specific glycosphingolipidsmediate epithelial-to-mesenchymal transition of human andmouse epithelial cell lines. Proc Natl Acad Sci USA. 2009;106(18):7461-6.
20. Vaid M, Singh T, Katiyar SK. Grape seed proanthocyanidinsinhibit melanoma cell invasiveness by reduction of PGE2 synthesisand reversal of epithelial-to-mesenchymal transition. PLoSONE. 2011;6(6):e21539.
21. Sato Y, et al. Epithelial-mesenchymal transition induced bytransforming growth factor-{beta}1/Snail activation aggravatesinvasive growth of cholangiocarcinoma. Am J Pathol. 2010;177(1):141-52.
22. Ghoul A, et al. Epithelial-to-mesenchymal transition and resistanceto ingenol 3-angelate, a novel protein kinase C modulator,in colon cancer cells. Cancer Res. 2009;69(10):4260-9.
23. Lo JF, et al. The epithelial-mesenchymal transition mediatorS100A4 maintains cancer-initiating cells in head and neck cancers.Cancer Res. 2011;71(5):1912-23.
24. Martin FT, et al. Potential role of mesenchymal stem cells(MSCs) in the breast tumour microenvironment: stimulation ofepithelial to mesenchymal transition (EMT). Breast Cancer ResTreat. 2010;124(2):317-26.
25. Sun T, et al. Expression and functional significance of Twist1 inhepatocellular carcinoma: its role in vasculogenic mimicry.Hepatology. 2010;51(2):545-56.
26. Yang MH, et al. Comprehensive analysis of the independenteffect of twist and snail in promoting metastasis of hepatocellularcarcinoma. Hepatology. 2009;50(5):1464-74.
27. Wang G, et al. A comparison of Twist and E-cadherin proteinexpression in primary non-small-cell lung carcinoma and correspondingmetastases. Eur J Cardiothorac Surg. 2011;39(6):1028-32.
28. Zheng G, et al. Disruption of E-cadherin by matrix metalloproteinasedirectly mediates epithelial-mesenchymal transitiondownstream of transforming growth factor-beta1 in renal tubularepithelial cells. Am J Pathol. 2009;175(2):580-91.
29. Thiery JP. Epithelial-mesenchymal transitions in tumour progression.Nat Rev Cancer. 2002;2(6):442-54.
30. Stein U, et al. The metastasis-associated gene S100A4 is a noveltarget of beta-catenin/T-cell factor signaling in colon cancer.Gastroenterology. 2006;131(5):1486-500. (Pubitemid 44708942)
31. Grigorian M, et al. Effect of mts1 (S100A4) expression on theprogression of human breast cancer cells. Int J Cancer. 1996;67(6):831-41. (Pubitemid 26348813)
32. Xue C, et al. The gatekeeper effect of epithelial-mesenchymaltransition regulates the frequency of breast cancer metastasis.Cancer Res. 2003;63(12):3386-94. (Pubitemid 36735899)
33. Mahon PC, et al. S100A4 contributes to the suppression ofBNIP3 expression, chemoresistance, and inhibition of apoptosisin pancreatic cancer. Cancer Res. 2007;67(14):6786-95. (Pubitemid 47105526)
34. Satelli A, Li S. Vimentin in cancer and its potential as amolecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033-46.
35. Hollingsworth MA, Swanson BJ. Mucins in cancer: protectionand control of the cell surface. Nat Rev Cancer. 2004;4(1):45-60. (Pubitemid 38082153)
36. Kohlgraf KG, et al. Contribution of the MUC1 tandem repeat andcytoplasmic tail to invasive and metastatic properties of a pancreaticcancer cell line. Cancer Res. 2003;63(16):5011-20. (Pubitemid 37022639)
37. Kim MA, et al. Prognostic importance of epithelial-mesenchymaltransition- related protein expression in gastric carcinoma. Histopathology.2009;54(4):442- 51.
38. Huang LY, et al. S100A4 over-expression underlies lymph nodemetastasis and poor prognosis in colorectal cancer. World JGastroenterol. 2011;17(1):69-78.
39. Toiyama Y, et al. Increased expression of Slug and Vimentin asnovel predictive biomarkers for lymph node metastasis and poorprognosis in colorectal cancer. Carcinogenesis. 2013;34(11):2548-57.
40. Yamashita N, et al. Vimentin as a poor prognostic factor fortriple-negative breast cancer. J Cancer Res Clin Oncol. 2013;139(5):739-46.
41. Zhong XY, et al. Positive association of up-regulated Cripto-1and down-regulated E-cadherin with tumour progression andpoor prognosis in gastric cancer. Histopathology. 2008;52(5):560-8.
42. Zhang Z, et al. Significance of TWIST expression and its associationwith E-cadherin in bladder cancer. Hum Pathol. 2007;38(4):598-606. (Pubitemid 46399887)
43. Ando H, et al. Prognostic significance of the expression of MUC1and collagen type IV in advanced gastric carcinoma. Br J Surg.2009;96(8):901-9.
44. Deng J, et al. The role of tumour-associated MUC1 in epithelialovarian cancer metastasis and progression. Cancer MetastasisRev. 2013;32(3-4):535-51.
45. Li ZS, Li Q. The latest 2010 WHO classification of tumors ofdigestive system. Zhonghua Bing Li Xue Za Zhi. 2011;40(5):351-4.
46. Huang J, et al. Prognostic significance and potential therapeutictarget of VEGFR2 in hepatocellular carcinoma. J Clin Pathol.2011;64(4):343-8.
47. Boyer B, Valles AM, Edme N. Induction and regulation of epi-thelial-mesenchymal transitions. Biochem Pharmacol. 2000;60(8):1091-9.
48. Onder TT, et al. Loss of E-cadherin promotes metastasis viamultiple downstream transcriptional pathways. Cancer Res. 2008;68(10):3645-54.
49. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actorplaying many roles. Am J Pathol. 2010;176(2):528-35.